Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
120,138,422
-
Total 13F shares
-
109,404,335
-
Share change
-
+21,854,209
-
Total reported value
-
$1,084,075,908
-
Put/Call ratio
-
599%
-
Price per share
-
$9.91
-
Number of holders
-
125
-
Value change
-
+$267,002,535
-
Number of buys
-
81
-
Number of sells
-
54
Institutional Holders of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) as of Q1 2024
As of 31 Mar 2024,
Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) was held by
125 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
109,404,335 shares.
The largest 10 holders included
Frazier Life Sciences Management, L.P., STATE STREET CORP, SUVRETTA CAPITAL MANAGEMENT, LLC, Rubric Capital Management LP, Polar Capital Holdings Plc, BlackRock Inc., VANGUARD GROUP INC, FRANKLIN RESOURCES INC, GILDER GAGNON HOWE & CO LLC, and MORGAN STANLEY.
This page lists
127
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.